Andy Chen
Stock Analyst at Wolfe Research
(2.65)
# 2,128
Out of 4,749 analysts
27
Total ratings
38.89%
Success rate
0.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMVT Immunovant | Downgrades: Peer Perform | n/a | $21.74 | - | 2 | Jan 3, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $697 | $655.13 | +6.39% | 2 | Nov 12, 2024 | |
| ALNY Alnylam Pharmaceuticals | Downgrades: Underperform | n/a | $271.31 | - | 2 | Nov 12, 2024 | |
| INCY Incyte | Initiates: Outperform | n/a | $74.16 | - | 1 | Oct 1, 2024 | |
| CLDX Celldex Therapeutics | Downgrades: Peer Perform | n/a | $24.49 | - | 3 | Sep 27, 2024 | |
| MLTX MoonLake Immunotherapeutics | Downgrades: Peer Perform | n/a | $45.99 | - | 2 | Aug 26, 2024 | |
| KYMR Kymera Therapeutics | Upgrades: Outperform | $65 | $39.59 | +64.18% | 2 | Aug 26, 2024 | |
| AKRO Akero Therapeutics | Initiates: Outperform | n/a | $54.08 | - | 1 | Jun 11, 2024 | |
| MDGL Madrigal Pharmaceuticals | Initiates: Outperform | n/a | $334.80 | - | 1 | Jun 11, 2024 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | n/a | $19.38 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $1.14 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $31.90 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $41.59 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $11.13 | +52.74% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $10.32 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $461.68 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $76.58 | -45.16% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $60 | $1.01 | +5,840.59% | 1 | Aug 8, 2023 |
Immunovant
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $21.74
Upside: -
argenx SE
Nov 12, 2024
Upgrades: Outperform
Price Target: $697
Current: $655.13
Upside: +6.39%
Alnylam Pharmaceuticals
Nov 12, 2024
Downgrades: Underperform
Price Target: n/a
Current: $271.31
Upside: -
Incyte
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $74.16
Upside: -
Celldex Therapeutics
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $24.49
Upside: -
MoonLake Immunotherapeutics
Aug 26, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $45.99
Upside: -
Kymera Therapeutics
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $39.59
Upside: +64.18%
Akero Therapeutics
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $54.08
Upside: -
Madrigal Pharmaceuticals
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $334.80
Upside: -
Viridian Therapeutics
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $19.38
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $1.14
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $31.90
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $41.59
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $11.13
Upside: +52.74%
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $10.32
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $461.68
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $76.58
Upside: -45.16%
Aug 8, 2023
Assumes: Buy
Price Target: $60
Current: $1.01
Upside: +5,840.59%